Oricell Therapeutics has announced the clearance of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for OriCAR-017, a new CAR-T cell therapy targeting GPRC5D, for the treatment of relapsed/refractory multiple myeloma (R/R MM).
The Progeria Research Foundation (PRF) has announced the Japanese approval of Zokinvy (lonafarnib) for treating Progeria and processing-deficient Progeroid Laminopathies (PL).
The US Food and Drug Administration (FDA) has approved an update to the label for Sanofi’s Dupixent (dupilumab), which now includes efficacy and safety data for patients aged 12 years and older with atopic dermatitis, specifically addressing moderate-to-severe hand and foot involvement.
AbbVie has announced the launch of Produodopa (foslevodopa/foscarbidopa), a new treatment for advanced Parkinson's disease (PD) patients in the European Union.
The US Food and Drug Administration (FDA) has granted priority review to Daiichi Sankyo and Merck’s biologics license application (BLA) for patritumab deruxtecan, to potentially treat non-small cell lung cancer (NSCLC) in adults.
SELLAS Life Sciences Group has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SLS009, a new CDK9 inhibitor aimed at treating relapsed/refractory Peripheral T-cell Lymphomas (PTCL).
The US Food and Drug Administration (FDA) has granted full approval for Calliditas Therapeutics’ Nefecon, a treatment licensed by Everest Medicines, for adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
Arcutis Biotherapeutics has received US Food and Drug Administration (FDA) approval for the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3%, to treat seborrheic dermatitis in individuals aged nine-years and older.
Merck, known as MSD outside of the US, and Canada, today announced that receipt of the US Food and Drug Administration (FDA) approval for WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor for the treatment of adult patients with advanced renal cell carcinoma (RCC).
NextPoint Therapeutics has announced that its investigational new drug (IND) application has been accepted by the US Food & Drug Administration (FDA) for NPX887.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.